reviewPsychopharmacology BulletinAug 12, 2025Closed access

A Systematic Review of Augmentation Strategies for Patients with Major Depressive Disorder

United BioSource Corporation (United Kingdom)

PubMed
Indexed incrossrefpubmed

Abstract

Major depressive disorder (MDD) is a leading cause of disability worldwide. Clinicians need to determine the most appropriate and effective interventions for patients who do not benefit from first-line treatment. A systematic review of the literature on augmentation strategies for major depression was conducted. A total of 32 eligible studies were included in the final review. Identified augmentation strategies included lithium, thyroid hormone, buspirone, stimulant drugs (methylphenidate and modafinil), and atypical antipsychotics (olanzapine, quetiapine, aripiprazole, and risperidone). Additional studies used other augmentation strategies (yohimbine, atomoxetine, inositol, testosterone, and lamotrigine), or…

Citation impact

68
total citations
FWCI
3.32
Percentile
99%
References
0
Citations per year

Authors

7

Topics & keywords

Keywords
  • Atomoxetine
  • Medicine
  • Quetiapine
  • Aripiprazole
  • Major depressive disorder
  • Tolerability
  • Escitalopram
  • Methylphenidate
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.